A new AI-driven framework, MapDiff, enhances inverse protein folding accuracy, accelerating the design of proteins for ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, ... Scaling 3D biology: Automation, imaging, and the future of high-throughput research.

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said ...

FILE PHOTO: FILE PHOTO: FILE PHOTO: An AstraZeneca logo is pictured in Brussels (Reuters) - AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the ...

In 2017, AstraZeneca reported (PDF) $4 billion in oncology revenue. Since then, the company’s annual cancer sales growth rate has ranged from 13% to 50%, culminating in oncology revenues topping ...

AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was widely used in the ...

AstraZeneca ADRs were up 5.6% to $75.20 as of noon ET and have gained nearly 12% so far this year. They reached their all-time high of $76.56 precisely one year ago. Article Sources ...